Intervention
vobramitamab duocarmazine
ClinicalTrials.gov intervention label
Clinical trials
3 shownA Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · 2023-06-13
TERMINATEDA Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsNCT05293496 · 2022-04-19
COMPLETEDMGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596 · 2018-11-21
TERMINATEDCommon conditions
Castration-Resistant Prostatic Cancer2Malignant Melanoma2Melanoma2Advanced Solid Tumor1Advanced Solid Tumor, Adult1Anal Cancer1Anal Neoplasm1Androgen-Independent Prostatic Cancer1Androgen-Insensitive Prostatic Cancer1Androgen-Resistant Prostatic Cancer1Carcinoma, Squamous Cell of Head and Neck1Epithelial Ovarian Cancer1Head and Neck Squamous Cell Carcinoma1Hepatocellular Cancer1Hormone Refractory Prostatic Cancer1Laryngeal Squamous Cell Carcinoma1Metastatic Castrate Resistant Prostate Cancer1Non Small Cell Lung Cancer1Non-small Cell Carcinoma1Non-small Cell Lung Cancer1Oral Squamous Cell Carcinoma1Pancreatic Ductal Carcinoma1Renal Cell Carcinoma1Small Cell Carcinoma1Small-cell Lung Cancer1
Leading sponsors
Trial status mix
TERMINATED2
COMPLETED1
Phase mix
PHASE12
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.